ERBB2 and neoplasm: The risk of relapse in the Luminal B subtype, which is characterized by positive hormonal receptors (HRs), non-amplified HER2, a higher tumor grade, a higher Ki-67 level, and more aggressive tumor behavior, is high and increases at a constant rate up to 10 years after diagnosis [3].